Phase II nonrandomized multicenter study of the impact of radiochemotherapy (65 Gy + cisplatin + 5FU) combined with cetuximab in patients presenting with locally advanced anal cancer

Trial Profile

Phase II nonrandomized multicenter study of the impact of radiochemotherapy (65 Gy + cisplatin + 5FU) combined with cetuximab in patients presenting with locally advanced anal cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 May 2014

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin; Fluorouracil
  • Indications Anal cancer
  • Focus Therapeutic Use
  • Acronyms ACCORD16
  • Most Recent Events

    • 16 Jan 2012 Planned End Date changed to 7 Oct 2014.
    • 07 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 18 Aug 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top